ONCO Oncopeptides AB (publ)

0.1617USD1.640 SEK · STO-3.02%Mkt Cap: 69.76M USDP/E: —

Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally…

Institutional holders1 on file

Key Statistics

Company
Market Cap69.76M USD
Enterprise Value68.24M USD
Revenue (TTM)10.21M USD
Gross Profit6.77M USD
Net Income (TTM)-24.61M USD
Revenue/Share0.03 USD
Last Price0.1617 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees71
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009414576
Valuation
P/E (Trailing)—
P/E (Forward)-2.31
PEG—
EV/EBITDA-3.78
EV/Revenue6.69
P/S6.84
P/B-39.05
EPS (TTM)-0.06 USD
EPS (Forward)-0.07 USD
52W Range
0.12478% of range0.5719
52W High0.5719 USD
52W Low0.1247 USD
Profitability
Gross Margin96.55%
Oper. Margin-178.92%
EBITDA Margin-176.86%
Profit Margin-350.94%
ROE423.81%
ROA-184.33%
ROIC—
ROCE-250.05%
Growth
Revenue Growth40.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.98M USD
CapEx (TTM)—
FCF Margin-114.35%
FCF Yield-16.73%
Net Debt2.33M USD
Net Debt/EBITDA-0.13
Net Debt/FCF—
Balance Sheet
Debt/Equity-2.37
Current Ratio3.75
Quick Ratio3.45
Book Value/Sh-0.0041 USD
Cash/Share0.03 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating3.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)0.2662 USD
Upside (mean)+64.6%
Target Range0.1972 USD – 0.3550 USD
0.1972+64.6% to mean0.3550
# Analysts3
Ownership
Shares Out.431.36M
Float379.39M
Insiders3.40%
Institutions13.15%
Technical
SMA 500.1887 (-14.3%)
SMA 2000.1689 (-4.2%)
Beta-0.50
S&P 52W Chg12.00%
Avg Vol (30d)5.67M
Avg Vol (10d)3.50M
Technical Indicators
RSI (14)40.2
MACD-0.0481
MACD Signal-0.0506
MACD Hist.+0.0025
BB Upper0.1790 USD
BB Middle0.1691 USD
BB Lower0.1592 USD
BB Width11.70%
ATR (14)0.0110 USD
Vol Ratio (20d)0.57x

About Oncopeptides (STO: ONCO)

›

Oncopeptides (STO: ONCO) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 71 employees.

The shares were at 1.640 SEK on 20 November 2026, down 70.3% over 52 weeks. Its 52-week range is 1.265 SEK to 5.800 SEK: the price is 71.7% below the high and 29.6% above the low.

Its market capitalisation is 707.43M SEK.

Oncopeptides reports return on equity of 423.8%, an operating margin of -178.9% and revenue up 40.7% year over year.

Its debt exceeds its cash by 23.58M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 3 analysts cover the stock, with an average rating of Hold; their mean price target of 2.700 SEK is 64.6% above the current price. The next earnings report is expected on 18 February 2027.